About Sana Biotechnology
Sana Biotechnology is a company based in Seattle (United States) founded in 2018 by Michael Mee, Jacob Rubens, and Geoffrey Von Maltzahn.. Sana Biotechnology has raised $821 million across 1 funding round from investors including Flagship Pioneering, Baillie Gifford and CPP Investments. The company has 194 employees as of December 31, 2024. Sana Biotechnology has completed 1 acquisition, including Oscine Therapeutics. Sana Biotechnology offers products and services including Engineered Cell Therapies and Drug Candidates. Sana Biotechnology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Seattle, United States
- Employees 194 as on 31 Dec, 2024
- Founders Michael Mee, Jacob Rubens, Geoffrey Von Maltzahn
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Sana Biotechnology, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-266.76 M5.82as on Dec 31, 2024
-
EBITDA
$-255.98 M13.21as on Dec 31, 2024
-
Total Equity Funding
$821 M (USD)
in 1 rounds
-
Latest Funding Round
$821 M (USD), Series D
Jun 25, 2020
-
Investors
Flagship Pioneering
& 10 more
-
Employee Count
194
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sana Biotechnology
Sana Biotechnology is a publicly listed company on the NASDAQ with ticker symbol SANA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Sana Biotechnology
Sana Biotechnology offers a comprehensive portfolio of products and services, including Engineered Cell Therapies and Drug Candidates. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops treatments by modifying cells to repair genes for diseases.
Advances therapies targeting cancer and autoimmune disorders through innovation.
Unlock access to complete
Unlock access to complete
Funding Insights of Sana Biotechnology
Sana Biotechnology has successfully raised a total of $821M through 1 strategic funding round. The most recent funding activity was a Series D round of $821 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series D — $821.0M
-
First Round
First Round
(25 Jun 2020)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2020 | Amount | Series D - Sana Biotechnology | Valuation | F-Prime Capital , Arch Venture Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Sana Biotechnology
Sana Biotechnology has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Flagship Pioneering, Baillie Gifford and CPP Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Sana Biotechnology
Sana Biotechnology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oscine Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Stem cell-based therapeutics are developed for CNS diseases.
|
2017 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Sana Biotechnology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Sana Biotechnology Comparisons
Competitors of Sana Biotechnology
Sana Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Sana Biotechnology
Frequently Asked Questions about Sana Biotechnology
When was Sana Biotechnology founded?
Sana Biotechnology was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Sana Biotechnology located?
Sana Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of Sana Biotechnology?
Steve Harr is the current CEO of Sana Biotechnology.
Is Sana Biotechnology a funded company?
Sana Biotechnology is a funded company, having raised a total of $821M across 1 funding round to date. The company's 1st funding round was a Series D of $821M, raised on Jun 25, 2020.
How many employees does Sana Biotechnology have?
As of Dec 31, 2024, the latest employee count at Sana Biotechnology is 194.
What does Sana Biotechnology do?
Sana Biotechnology was founded in 2018 and is headquartered in Seattle, United States. Operations focus on the biotechnology sector, where genetically engineered cell therapies are created to address disorders such as Non-Hodgkin lymphoma, multiple myeloma, diabetes, and central nervous system conditions. Drug candidates like SC291, SC255, SC451, and SC379 are advanced through gene therapy and editing techniques to reprogram cells in the body or replace damaged tissues.
Who are the top competitors of Sana Biotechnology?
Sana Biotechnology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Sana Biotechnology offer?
Sana Biotechnology offers Engineered Cell Therapies and Drug Candidates.
Is Sana Biotechnology publicly traded?
Yes, Sana Biotechnology is publicly traded on NASDAQ under the ticker symbol SANA.
How many acquisitions has Sana Biotechnology made?
Sana Biotechnology has made 1 acquisition, including Oscine Therapeutics.
Who are Sana Biotechnology's investors?
Sana Biotechnology has 11 investors. Key investors include Flagship Pioneering, Baillie Gifford, CPP Investments, Arch Venture Partners, and F-Prime Capital.
What is Sana Biotechnology's ticker symbol?
The ticker symbol of Sana Biotechnology is SANA on NASDAQ.